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Although current immunosuppression is highly effective in
avoiding acute rejection, it is associated with nephrotoxicity,
cardiovascular morbidity, infection, and cancer. Thus, new
drugs dealing with new mechanisms, as well as minimizing
comorbidities, are warranted in renal transplantation. Few
novel drugs are currently under investigation in Phase I, II,
or III clinical trials. Belatacept is a humanized antibody that
inhibits T-cell co-stimulation and has shown encouraging
results in Phase II and III trials. Moreover, two new small
molecules are under clinical development: AEB071 or
sotrastaurin (a protein kinase C inhibitor) and CP-690550 or
tasocitinib (a Janus kinase inhibitor). Refinement in selecting
the best combinations for the new and current
immunosuppressive agents is probably the main challenge
for the next few years.
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Kidney transplantation is the treatment of choice for end-
stage renal disease owing to the use of potent immuno-
suppressive therapy. Current immunosuppression is highly
effective in avoiding acute rejection, but it is associated with
nephrotoxicity, cardiovascular morbidity, infection, and
cancer. Therefore, the improvement in short-term graft
survival has not been reflected in improved long-term
outcomes.1 Current immunosuppression strategies are pri-
marily based on the use of an induction regimen using a
monoclonal or polyclonal antibody, followed by maintenance
immunosuppression based on a calcineurin inhibitor (CNI),
an anti-proliferative agent, and low-dose corticosteroids.2
Several CNI minimization and withdrawal protocols have
been attempted with varied results.3 The use of mammalian
target of rapamycin inhibitors for CNI minimization or
withdrawal has been hampered by their adverse side-effect
profile.4,5 Therefore, it is accepted that CNIs currently remain
the cornerstone of maintenance immunosuppression in renal
transplantation.6 Undoubtedly, new drugs dealing with new
mechanisms, as well as minimizing comorbidities, are
warranted in renal transplantation. The present trend in
drug development is focused on preservation of long-term
function and minimization of the adverse events of
immunosuppressive drugs.7 Several small molecules and
biological agents are currently being studied. Belatacept is a
humanized antibody that inhibits T-cell co-stimulation and
has shown encouraging results in Phase II and III trials.
Moreover, two new small molecules are under clinical
development: AEB071 or sotrastaurin (a protein kinase C
(PKC) inhibitor) and CP-690550 (a Janus kinase (JAK)
inhibitor). All three drugs are excellent examples to show
how difficult it is to develop new immunosuppressants to
overcome the CNI toxicities. Refinement in selecting the
best combinations for the new and some current immuno-
suppressive agents is probably the main challenge for next
few years.
BELATACEPT
In the near future, belatacept would be the first biological
agent for use in long-term maintenance regimen in organ
transplantation. Its parent molecule was CTLA4-Ig (abata-
cept), and resulted from the fusion of the extracellular
domain of CTLA4 with the constant region fragment of
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human IgG1.8 As CTLA4 shows high affinity for CD80/86,
CTLA4-Ig may block antigen-presenting cell co-stimulation
of T cells through CD28, thereby abrogating the immune
response. Abatacept was proved to be highly effective for
autoimmune T-cell-mediated autoimmune disorders,9 but
inadequate as a maintenance immunosuppressive agent in
non-human primate models of transplantation.10 Potential
explanation could be that abatacept is significantly less potent
in inhibiting CD86-dependent as opposed to CD80 co-
stimulation.11 A daughter molecule LEA29Y (belatacept)
with two amino-acid substitutions (L104-4E and A29-4Y)
was developed.12 Belatacept was found to bind four times
more avidly to CD86 and two times more avidly to
CD80 than the parent abatacept. This improved binding
resulted in B10-fold more potent inhibition of T-cell
activation.12 Belatacept efficacy was demonstrated in several
non-human primate preclinical models of renal transplanta-
tion, particularly in combination with basiliximab and
other immunosuppressants such as mycophenolate mofetil
(MMF). In addition, belatacept was suggested as being
capable of preventing development of donor-specific anti-
bodies.13
Clinical development of belatacept
The first clinical trial on the use of belatacept in clinical renal
transplantation was a Phase II non-inferiority trial compar-
ing the efficacy of belatacept vs cyclosporine (CsA) for
prevention of acute rejection at 6 months post-transplant.14
Belatacept was administered as less (LI) or more intensive
(MI) schedule. All patients also received MMF and
corticosteroids as maintenance immunosuppression, and
induction with basiliximab. At 6 months, the incidence of
acute rejection was similar in all three groups ranging from
6 to 8%. The LI group experienced a higher incidence of
subclinical rejection and treated episodes of subclinical
rejection compared with the MI and CsA groups. Glomerular
filtration rate was significantly higher in the belatacept
groups compared with the CsA arm. Protocol biopsies
demonstrated a significant reduction in the incidence of
chronic allograft nephropathy in the belatacept group.
Cardiovascular profile improved in the belatacept groups as
they had a statistically significant lower risk of developing
diabetes, need for treatment of hyperlipidemia, and a lower
incidence of hypertension.
Two Phase III studies have been recently published. The
BENEFIT (Belatacept Evaluation of Nephroprotection and
Efficacy as First line Immunosuppression Trial) study is a
3-year Phase III clinical trial, which randomized patients to
three groups as previously described. Patient and graft
survival are similar in three groups.15,16 However, the
incidence of acute rejection was greater in MI (22%) and
LI (17%) belatacept compared with CsA (7%), although no
apparent impact on graft survival was demonstrated. Most
acute rejection episodes occurred within the first 3 months
and severity was higher in belatacept compared with CsA-
treated patients. At the end of 2 years, glomerular filtration
rate continued to be significantly higher in the belatacept-
treated patients. Belatacept-treated patients also had sus-
tained benefits in their cardiovascular and metabolic risk
profile. The BENEFIT-EXT (Belatacept Evaluation of
Nephroprotection and Efficacy as First-line Immunosuppres-
sion Trial—EXTended criteria donors) study is a 3-year
randomized Phase III study in patients receiving an
extended-criteria-donor kidney allograft.17 Patient and graft
survival were similar in all the three groups. Renal function
was statistically superior in MI belatacept vs CsA but not in
LI vs CsA group. The incidence of chronic allograft
nephropathy was similar in the three groups, probably
because of the presence of renal damage at baseline.
Interestingly, cardiovascular risk factors were lower in the
belatacept-treated patients. The 2-year results showed similar
trend.16
Vincenti et al.18 recently published the 5-year safety
data of their initial Phase II study. Belatacept-treated patients
did not have a higher frequency of serious infections or
post-transplant lymphoproliferative disorder (PTLD) com-
pared with CsA. Remarkably, major cardiac adverse events
occurred more frequently with CsA (2% belatacept vs
12% CsA).
Of the three major trials described above, a total of 13
patients in the belatacept groups have been diagnosed with
PTLD (1.4%) compared with only one CsA patient (0.2%).
Of the 13 cases of PTLD identified, six developed PTLD of
the central nervous system. This is a diagnosis to be
concerned about considering that this involvement is seldom
encountered in solid organ transplantation.19 The majority of
patients who developed PTLD had known risk factors for
PTLD, including pre-transplant EBV-seronegative recipients,
those receiving lymphocyte-cell-depleting agents, and those
having a primary EBV infection.
In these lines, a recent Phase II analysis that excluded
transplant recipients who were EBV seronegative before
transplant has yet to report any cases of PTLD.20 The absence
of PTLD in this analysis may be evidence enough to avoid use
of belatacept in those recipients who are EBV seronegative
before transplant. A total of 89 patients were randomized to
receive belatacept-MMF, belatacept-sirolimus, or tacrolimus-
MMF. All patients received thymoglobulin induction. Renal
function was better in the belatacept-treated groups. Acute
rejection occurred in four, one, and one patient in the
belatacept-MMF, belatacept-SRL, and TAC-MMF groups,
respectively. The authors concluded that the use of belatacept
in renal transplantation may allow CNI and corticosteroid
avoidance, with acceptable rates of acute rejection and
improved glomerular filtration rate.
Results from a Phase II study to evaluate conversion from
a CNI-based regimen to belatacept have been recently
published.21 This randomized, open-label study included
171 patients, 6 months to 3 years post-transplant, who were
receiving CNI-based immunosuppression and had stable
renal function. Patients were randomized into one of two
treatment groups: conversion to belatacept 5mg/kg with CNI
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discontinuation (n¼ 83), or continued CNI therapy (n¼ 88).
At month 12, the mean change from baseline in glomerular
filtration rate was higher in the belatacept group compared
with the CNI group. Six patients in the belatacept group had
acute rejection episodes, all within the first 6 months, and all
resolved with no allograft loss. The overall safety profile was
similar in each treatment group.
In summary, some concerns appear with the use of
belatacept. It was originally anticipated that co-stimulation
blockade would be successful in achieving immunological
allograft tolerance; however, based on higher acute rejection
rates, this does not appear to be the case, probably because of
its inhibitory effect on regulatory T-cell expansion by MI
belatacept regime in combination with basiliximab. Another
limitation of this medication is that administration requires
an intravenous infusion. As there is increased PTLD risk in
EBV-seronegative patients, belatacept should be prescribed
for EBV-seropositive patients only. Nevertheless, clinical trials
suggest that the use of belatacept can lead to better renal
function along with a lower incidence of diabetes and
cardiovascular risk factors. Currently, on the basis of the
manufacturer’s recommendation, the Food and Drug Ad-
ministration is reviewing the LI-dosing regimen of belatacept
as an immunosuppressive regimen in kidney transplant
recipients. This LI belatacept protocol is associated with low
acute rejection rates, but maintains a renal and cardiovas-
cular favorable profile.
JANUS KINASE INHIBITORS (CP-690550 OR TASOCITINIB)
Janus kinases are cytoplasmic tyrosine kinases involved in cell
proliferation, growth, and survival by integrating extracel-
lular signaling induced by cytokines.22 For instance, after co-
stimulation, type I cytokines (interleukin (IL)-2, IL-4, IL-7,
IL-9, IL-15, IL-2) bind to cell surface receptor members of the
cytokine receptor common gamma (gc) chain family and
activate JAKs. Nevertheless, JAKs participate in the signaling
of many cytokine receptors in several cell types. Activation of
JAKs induces cytokine receptor phosphorylation, as well as
recruitment of signal transducers and activators of transcrip-
tion, and catalyzes phosphorylation of signal transducers and
activators of transcription that facilitates its dimerization and
transportation to the nucleus where they regulate gene
expression. There are four JAKs identified in mammals: JAK-
1, 2, 3, and tyrosine kinase-2. JAK1 is activated by gp130
cytokines, type I interferon, interferon-g, and bc cytokines;
its deficiency causes neurological defects and severe com-
bined immunodeficiency. JAK2 is activated by erythropoie-
tin, thrombopoietin, prolactin, growth hormone, gc
cytokines, interferon-g, and IL-12; its deficiency is lethal
because of defective erythropoiesis. JAK3 is mainly expressed
in hematopoietic cells and just activated by gc cytokines;
its deficiency causes severe combined immunodeficiency.
Tyrosine kinase-2 is activated by gp130 cytokines, type I
interferon, IL-12, and IL-23; its deficiency induces minor
effects.23 Therefore, compared with other JAKs, which are
ubiquitous and activated by several types of cytokines, its
specificity makes JAK3 an interesting target for immunosup-
pression. However, there is high structural similarity between
JAK2 and JAK3 that makes it difficult to synthesize
compounds that are able to inhibit JAK3 without affecting
JAK2. This is crucial as the safety profile depends on JAK3
inhibition selectivity.
CP-690550 or tasocitinib is a synthetic orally available
inhibitor of JAK3 that maintains reasonable selectivity for
JAK3. In vitro and animal studies demonstrated its potency
and capacity to prevent rejection even in cynomolgus
monkeys.24 Therefore, CP-690550 is currently under clinical
development.
A double-blinded, placebo-controlled Phase I trial asses-
sing safety and tolerability of CP-690550 (5, 15, 30mg b.i.d.)
in renal transplant recipients reported that most adverse
events were gastrointestinal or infectious.25 In addition, high
CP-690550 doses were associated with reduction of hemo-
globin levels, demonstrating its inhibitory effect on JAK2.
Further studies confirm that, although highly specific
for JAK3, CP-690550 also inhibits JAK2 to some extent.26
A 6-month Phase II trial and its extension to 12 months have
been published.27 In this trial, 61 adult renal transplant
recipients were randomized to CP-690550 15mg or 30mg
b.i.d., vs tacrolimus in combination with an IL-2 receptor
antagonist, MMF, and steroids. In the high-dose arm, an
increased incidence of BK virus nephropathy and cytomega-
lovirus infection required a protocol amendment, based on
planned MMF withdrawal and rapid steroid taper. The
consequence was 21.1% incidence of acute rejection in the
high-dose arm. However, the low-dose arm provided
excellent results that showed a 5.3% incidence of acute
rejection and 76.9ml/min glomerular filtration rate. These
results were confirmed in the 12-month extension protocol
in which CP-690550 was reduced to 15mg b.i.d. In the
CP-690550 arms, there was a trend toward more frequent
anemia and neutropenia. Overall, the efficacy/safety profile of
CP-690550 at 15mg b.i.d. was comparable to tacrolimus,
with the exception of a higher rate of viral infection. These
results were used for designing ongoing protocols exploring
the effects of a lower dose of CP-690550 in renal
transplantation (5 and 10mg b.i.d.). These preliminary data
suggest that CP-690550 has the potential to improve current
immunosuppression armamentarium. However, there still
exist some concerns. Anemia is a common adverse event that
has been reported in 30% of patients enrolled in the Phase II
trial; lower doses and new combination strategies should be
explored and, finally, new molecules with high JAK3
selectivity warranted.
SOTRASTAURIN (AEB071)
Protein kinase C has an important role in the immune
response. It is well known that T-cell receptor activation with
co-stimulation signaling leads to PKC activation and IL-2
production.28–30 On the basis of cofactor requirements, there
are at least 10 PKC isoforms that can be divided into three
categories: classical or conventional, novel, and atypical. The
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a, b, and y isoforms appear to have clear roles in either T- or
B-cell signaling, thus suggesting that inhibition of several
isoforms are needed to achieve full immunosuppression. The
best characterized is PKCy, which is mostly restricted to T
lymphocytes and mediates activation of the transcription
factors activator protein-1 and nuclear factor kB, leading to
IL-2 production. In fact, knockout of PKCy impairs T-cell
activation in mice.31
Sotrastaurin is a small molecule that inhibits PKC activity,
including classical (a, b) and novel (d, e, Z, y) isoforms.
Similar to CNIs, sotrastaurin principally inhibits PKCy acting
on IL-2 gene promoters. Nevertheless, it has insignificant
effect on downstream targets of calcineurin, such as nuclear
factor of activated T cells.32,33 This feature led investigators to
hypothesize that sotrastaurin can be as potent as CNIs
without displaying nephrotoxicity. Non-human primate and
healthy human volunteer studies have endorsed those in vitro
sotrastaurin characteristics. Sotrastaurin, in monotherapy or
in combination with other immunosuppressants, prolongs
allograft survival in rats and cynomolgus monkeys.34,35
Preclinical and early clinical safety data demonstrated no
signs of nephrotoxicity or hepatotoxicity, and no metabolic
or blood pressure effects at standard exposures.28,29 Gastro-
intestinal effects were the dose-limiting toxicities in all species
tested preclinically. In vitro tests indicated a modest potential
for QT prolongation. However, in healthy volunteer studies,
QT effects could not be confirmed at therapeutic doses. A
reversible increase in mean ventricular heart rate was
observed at a single dose of 500mg, with mean heart rates
remaining within the normal range.36 Similar to CNIs and
mammalian target of rapamycin inhibitors, compensatory
reduction in the dose of sotrastaurin is warranted when
strong CYP3A4 inhibitors are coadministered. 37
In a proof-of-concept study in patients with psoriasis,
clinical severity was reduced by 69% after a 2-week treatment
with sotrastaurin. This effectiveness was dose dependent and
achieved with good drug tolerability.38
Results in renal transplantation have not been as good as it
was expected.36 In one trial, patients were initially placed on
tacrolimus/sotrastaurin/steroids treatment and then under-
went conversion from tacrolimus to sodium mycophenolate
(MPA) at 3 months, which resulted in an increased incidence
of the primary composite endpoint (acute rejection, graft
loss, or death) in the sotrastaurin arm. In another trial,
de novo CNI-free arm of sotrastaurin/MPA/steroids was
compared with tacrolimus/MPA/steroids. Again, acute rejec-
tion rate was higher in the sotrastaurin arm. These studies
were prematurely stopped and the results from the first
sotrastaurin Phase II trial in renal transplantation have been
recently published.36 A total of 216 patients were rando-
mized, 74 were allocated to control-MPAþ standard expo-
sure tacrolimus, 76 to sotrastaurin 200mg b.i.d.þ standard
exposure tacrolimus, and 66 to sotrastaurin 200mg
b.i.d.þ reduced exposure tacrolimus. Sotrastaurin-treated
recipients who met conversion criteria at month 3 were
converted to a CNI-free regimen of sotrastaurin 200mg
b.i.d.þMPA 720mg b.i.d. During the 3-month pre-conver-
sion period, all regimens showed comparable efficacy to
control for the composite endpoint (acute rejection, graft
loss, or death). However, after conversion from tacrolimus to
MPA, both sotrastaurinþMPA regimens were inferior to the
control for the primary composite endpoint. Thus, compo-
site efficacy failure rates were 7.8, 44.8, and 34.1% at study
end in the control, sotrastaurinþ standard exposure tacro-
limus, and sotrastaurinþ reduced exposure tacrolimus. The
majority of biopsies in the sotrastaurin groups were Banff IA
or IB. Therefore, the initial sotrastaurin-tacrolimus regimen
was efficacious and well tolerated, but the post-conversion
sotrastaurin-MPA regimen showed inadequate efficacy. With
regard to adverse events, gastrointestinal toxicities were
frequent, mild, and similar in all groups.36 Tachycardia
occurred at a higher incidence in both sotrastaurin groups
compared with control in the peritransplant period, but
returned to baseline levels at 1 week. Interestingly, the
incidence of new-onset diabetes in the control group (14.9%)
was nearly twice that in the sotrastaurin groups (6.7 and
7.7%). The sotrastaurin-tacrolimus combination seems to be
as effective as tacrolimus-MPA, at least in the short term.
This may be the rationale for designing studies of
sotrastaurin with CNI minimization.28 In these lines, it has
been recently reported that tacrolimus does not alter the
pharmacokinetics of sotrastaurin; however, sotrastaurin
increases tacrolimus area under the concentration-time curve
by twofold.39
Given the lack of efficacy of the sotrastaurinþMPA
regimen, attention has turned to explore sotrastaurin in
combination with everolimus in a new Phase II trial. This
trial is currently underway in Europe. There is some
pharmacokinetic interaction between both drugs. Sotrastaur-
in exposure does not seem to be altered by everolimus, but
sotrastaurin increases everolimus exposure by 20%.40
CONCLUSION
This review clearly illustrates the difficulty faced in develop-
ing new immunosuppressants to overcome the CNI toxi-
cities. On one hand, belatacept given in combination with
basiliximab, steroids, and MMF is associated with both PTLD
in EBV-negative recipients and more rejection. On the other
hand, tasocitinib is highly effective in preventing rejection,
but is associated with some over-immunosuppression
complications. Finally, sotrastaurin shows lack of efficacy in
combination with an antiproliferative agent. Altogether, these
findings suggest that refinement in selecting the best
combinations for the new and some current immunosup-
pressive agents is probably the main challenge for the next
years.
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